Crucell is developing a recombinant malaria vaccine based on its proprietary AdVac^® technology and produced on its proprietary PER.C6^® production technology. For further information on this program please refer to our R&D section of the website or download the following documents.

• About Malaria (PDF)

• Developing a Malaria Vaccine (PDF)

24 January 2007: Crucell awarded EU grant to develop malaria vaccine

22 December 2006: Crucell subsidiary awarded EU grant to develop malaria vaccine

19 December 2006: Crucell and NIH Gain Approval and Move to Recruitment for Malaria Vaccine Clinical Study

1 August 2005: Harvard and Crucell Receive $19.2 million NIH Grant to Develop Next-Generation AdVac®-based Vaccines

23 December 2004: Crucell Secures € 2 Million Grant for Malaria Collaboration from Dutch Ministry of Economic Affairs

30 March 2004: Crucell Receives NIH Support for Candidate Malaria Vaccine Development

14 November 2003: Crucell Presents Encouraging Results of its Malaria Vaccine Program

22 October 2003: Crucell Announces Malaria Vaccine Program in Collaboration with New York University, Walter Reed Army Institute of Research and GlaxoSmithKline

Publications related to Crucell’s malaria vaccine program are listed below. Please click on any of these to access the abstracts of the articles. For more Crucell scientific papers please use search word ‘Crucell’ at PubMed, http://www.ncbi.nlm.nih.gov./entrez/query.fcgi.

Ophorst, O.J., et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun. 2006. 74, 313-320.

Barouch DH et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity J Immunol. 2004. 172(10), 6290-6297.

Visit Useful Links